Physician profile
Cara Lyle
NPI 1891114328
$5,578.38
in general payments reported to CMS, 2019-2025
21 companies · $2,570 in 2025
The $2,570 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $375 · 2021: $325 · 2022: $179 · 2023: $1,236 · 2024: $400 · 2025: $2,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891 · Grant: $1,500 · Travel and Lodging: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.94 |
| Grant | $1,500.00 |
| Travel and Lodging | $814.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,760.77 | 2024-2025 | Endurant Iis |
| Terumo Medical Corporation | $1,049.65 | 2023-2025 | Glidewire, Glidesheath Slender, Tr Band |
| Medtronic Vascular, INC. | $868.95 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $505.56 | 2024-2025 | Gore Viabahn Vbx Balloon Expandable Endo, Gore Excluder Iliac Branch Endoprosthesis, Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Cook Medical LLC | $349.89 | 2021-2025 | Zenith Alpha, Zenith, Zenith Spiral-Z |
| Abbott Laboratories | $164.19 | 2021-2023 | Starclose Se |
| Boston Scientific Corporation | $123.21 | 2025 | Enroute Transcarotid Stent |
| Endologix LLC | $104.72 | 2021 | |
| Bolton Medical INC | $102.14 | 2022-2025 | Gelweave |
| Shockwave Medical, INC | $76.57 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $75.89 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $75.42 | 2024-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $66.35 | 2023 | |
| Janssen Pharmaceuticals, INC | $56.36 | 2021-2022 | |
| Abbvie INC. | $51.26 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $44.70 | 2021 | |
| Amgen INC. | $32.80 | 2022-2023 | Repatha |
| Kci USA, INC. | $20.16 | 2021 | |
| Lemaitre Vascular, INC. | $18.28 | 2025 | Artegraft Vascular Graft |
| Pfizer INC. | $16.99 | 2023 | |
| Merck Sharp & Dohme LLC | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Lyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.